BridgeMD
New treatment option for IgA Nephropathy (IgAN)
Official title Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
ClinicalTrials.gov ID: NCT07056595
What this study is testing
What is Finerenone?
Finerenone is an investigational medicine, being studied as a potential treatment for iga nephropathy (igan).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- : IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (\> 18 years) with the primary IgAN diagnosed by kidney biopsy;
- Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;
- Blood pressure \< 140/90 mm Hg
- 24-hour urinary albumin excretion \> 300 mg
You likely can't join if
- Kidney transplantation in medical history
- Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;
- Heart failure with ejection fraction \<40%;
- Acute myocardial infarction and/or stroke less then 3 months before including in trial;
- Presence ANCA in serum
- Ongoing immunosuppressive treatment
See the full eligibility criteria
- Adults (\> 18 years) with the primary IgAN diagnosed by kidney biopsy;
- Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;
- Blood pressure \< 140/90 mm Hg
- 24-hour urinary albumin excretion \> 300 mg
- Kidney transplantation in medical history
- Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;
- Heart failure with ejection fraction \<40%;
- Acute myocardial infarction and/or stroke less then 3 months before including in trial;
- Presence ANCA in serum
- Ongoing immunosuppressive treatment
- eGFR \< 20 ml/min
- Pregnancy and breastfeeding
- Uncontrolled blood pressure
The study team makes the final eligibility decision.
Where it's taking place
- Moscow, Russia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Moscow, Russia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.